ReviewThe international journal of biochemistry & cell biology2006
Sickle cell disease and nitric oxide: a paradigm shift?
Review in The international journal of biochemistry & cell biology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 5 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Interventions for treating leg ulcers in people with sickle cell disease.The Cochrane database of systematic reviews · 2021Pooled it
- Antibiotics for treating osteomyelitis in people with sickle cell disease.The Cochrane database of systematic reviews · 2016Pooled it
- Antibiotics for treating acute chest syndrome in people with sickle cell disease.The Cochrane database of systematic reviews · 2015Pooled it
- Interventions for treating leg ulcers in people with sickle cell disease.The Cochrane database of systematic reviews · 2014Pooled it
- Interventions for treating painful sickle cell crisis during pregnancy.The Cochrane database of systematic reviews · 2009Pooled it
- Thrombocytosis and the generation of platelet-derived microparticles in the pathophysiology of sickle cell disease.British journal of haematology · 2026Review
- Gene-environmental influence of space and microgravity on red blood cells with sickle cell disease.NPJ genomic medicine · 2024Review
- Respiratory management of acute chest syndrome in children with sickle cell disease.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease.EJHaem · 2024Article
- Beat-to-beat analysis of hemodynamic response to mental and psychological stress in sickle cell anemia.Journal of sickle cell disease · 2024Article
- Cutaneous manifestations of sickle cell disease: an updated review.Archives of dermatological research · 2023Review
- Neuregulin-1 attenuates hemolysis- and ischemia induced-cerebrovascular inflammation associated with sickle cell disease.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2023Article
- Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.Biomedicines · 2023Review
- Clinical Vignettes Part I.Hematology/oncology clinics of North America · 2022Review
- Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.Molecules (Basel, Switzerland) · 2022Article
- Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease.Biomolecules · 2022Article
- Development and Validation of the Patient/Caregiver Reported Hydroxyurea Evaluation of Adherence for Life (HEAL) Scale.Patient preference and adherence · 2022Article
- Severe Persistent Pain and Inflammatory Biomarkers in Sickle Cell Disease: An Exploratory Study.Biological research for nursing · 2022Article
- Testosterone Deficiency in Sickle Cell Disease: Recognition and Remediation.Frontiers in endocrinology · 2022Review
- Leg Ulcers: A Report in Patients with Hemoglobin E Beta Thalassemia and Review of the Literature in Severe Beta Thalassemia.Acta haematologica · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Traditionally the pathophysiology of sickle cell disease is thought to result from the polymerization of hemoglobin S in red cells, under hypoxic conditions, resulting in the occlusion of blood vessels. Adhesion of cells to the venular endothelium also appears to play a role. Recent studies have also suggested that in addition to the polymerization of hemoglobin S in the red blood cell, a deficiency of the endogenous vasodilator, nitric oxide may be involved. Hemoglobin released as a result of hemolysis rapidly consumes nitric oxide resulting in a whole program of events that inhibit blood flow. Therapies directed at decreasing the destruction of nitric oxide, increasing the production of nitric oxide, or amplifying the nitric oxide response may prove beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.